ADMA Biologics Posts Record Earnings Amid Fraud Lawsuit

ADMA Biologics reported fiscal 2026 Q2 earnings on August 5, 2026, highlighting continued profitability growth despite emerging legal challenges. The company met its full-year revenue guidance projections, driven by strong ASCENIV performance, while announcing plans for significant share repurchases. However, the positive financial results are overshadowed by a newly filed securities fraud class action alleging channel stuffing practices that initially impacted investor sentiment earlier in the year.

Revenue

The total revenue of ADMA Biologics increased by 2.0% to $124.39 million in 2026 Q2, up from $121.98 million in 2025 Q2.

Earnings/Net Income

ADMA Biologics's EPS rose 21.4% to $0.17 in 2026 Q2 from $0.14 in 2025 Q2, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $37.82 million in 2026 Q2, marking 10.5% growth from $34.22 million in 2025 Q2. Remarkably, in 2026 Q2, the company set a new record high for fiscal Q2 net income, the highest in 15 years. The company demonstrated robust operational efficiency and strong margin expansion in the second quarter.

Price Action

The stock price of ADMA Biologics has edged up 2.89% during the latest trading day, has climbed 6.31% during the most recent full trading week, and has edged up 1.09% month-to-date.

Post-Earnings Price Action Review

Following the earnings release, ADMA Biologics exhibited modest upward momentum, with the stock price rising 2.89% on the most recent trading day and gaining 6.31% over the full preceding week. This recent trajectory reflects a slight recovery in investor confidence despite ongoing volatility. The stock has also seen a marginal 1.09% increase month-to-date, suggesting a stabilization after earlier sharp declines. While the immediate post-earnings reaction has been positive, the broader market sentiment remains influenced by the recent securities fraud allegations. Investors are closely monitoring how the company addresses these legal concerns while maintaining its strong financial performance in the subsequent trading sessions.

CEO Commentary

Adam Grossman, President and Chief Executive Officer, highlighted strong execution and ASCENIV’s accelerating growth trajectory, noting a 24% year-over-year revenue increase to $102.9 million in the second quarter of 2026. He emphasized robust demand drivers, including increased physician adoption, broader prescriber engagement, and higher patient utilization, with June recording the strongest sequential month-over-month growth since early 2024. Concurrently, BIVIGAM demand stabilized, yielding sequential improvements in utilization and revenue. Grossman expressed confidence in sustained growth for the remainder of 2026, supported by expanding real-world evidence demonstrating significant reductions in infection-related hospitalizations and healthcare resource utilization among complex primary immunodeficiency patients.

Guidance

The company reiterates its full-year 2026 financial guidance, projecting total revenue between $530 million and $560 million. Adjusted net income is expected to range from $170 million to $200 million, while adjusted EBITDA is guided to fall between $265 million and $300 million. Management maintains this outlook based on sustained competitive dynamics and pricing pressures within the U.S. immune globulin market. ASCENIV remains the principal growth driver, supported by accelerating demand and an expanding body of clinical evidence. The company expresses confidence in meeting or exceeding these guidance ranges, citing accelerating ASCENIV demand, stabilizing BIVIGAM performance, and strong cash generation, which also supports a target of completing at least $200 million in share repurchases during 2026.

Additional News

ADMA Biologics faces significant legal scrutiny following the filing of a securities fraud class action lawsuit, Mazzarino v. ADMA Biologics, Inc., in the U.S. District Court for the District of New Jersey. The lawsuit alleges that the company engaged in a channel stuffing scheme to artificially inflate 2025 revenue growth, contradicting reports of actual declines. Lead plaintiff deadlines are set for August 10, 2026. The legal action stems from a March 2026 investigative report by Culper Research, which claimed ADMA used rebates and extended payment terms to induce distributors to stock excess inventory. This disclosure previously triggered substantial stock declines, including a 16.6% drop on March 24, 2026. The allegations include failure to disclose related-party transactions and misrepresentations regarding demand trends. Investors are advised to review their rights as the case proceeds, with Bleichmar Fonti & Auld LLP leading the representation. The legal challenges pose potential risks to the company’s reputation and financial stability despite its current earnings strength.